KR102120620B1 - 면역글로불린을 이용한 점막염의 치료 - Google Patents

면역글로불린을 이용한 점막염의 치료 Download PDF

Info

Publication number
KR102120620B1
KR102120620B1 KR1020147028264A KR20147028264A KR102120620B1 KR 102120620 B1 KR102120620 B1 KR 102120620B1 KR 1020147028264 A KR1020147028264 A KR 1020147028264A KR 20147028264 A KR20147028264 A KR 20147028264A KR 102120620 B1 KR102120620 B1 KR 102120620B1
Authority
KR
South Korea
Prior art keywords
composition
iga
mucositis
cells
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147028264A
Other languages
English (en)
Korean (ko)
Other versions
KR20140145587A (ko
Inventor
크리스토프 애비
존야 크리스티나 뤼에르
알렉산더 샤웁
실비아 미셰르
아드리안 취르허
체드릭 피에르 포나르부륵
Original Assignee
체에스엘 베링 아게
우니베르지테트 베른
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 아게, 우니베르지테트 베른 filed Critical 체에스엘 베링 아게
Publication of KR20140145587A publication Critical patent/KR20140145587A/ko
Application granted granted Critical
Publication of KR102120620B1 publication Critical patent/KR102120620B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147028264A 2012-03-09 2013-03-08 면역글로불린을 이용한 점막염의 치료 Active KR102120620B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12158939.4 2012-03-09
EP12158939.4A EP2636683A1 (en) 2012-03-09 2012-03-09 Treatment of mucositis with Immunoglobulin
PCT/EP2013/054722 WO2013132063A1 (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin

Publications (2)

Publication Number Publication Date
KR20140145587A KR20140145587A (ko) 2014-12-23
KR102120620B1 true KR102120620B1 (ko) 2020-06-10

Family

ID=45808320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147028264A Active KR102120620B1 (ko) 2012-03-09 2013-03-08 면역글로불린을 이용한 점막염의 치료

Country Status (10)

Country Link
US (1) US9546209B2 (enExample)
EP (2) EP2636683A1 (enExample)
JP (1) JP6238910B2 (enExample)
KR (1) KR102120620B1 (enExample)
CN (1) CN104254543B (enExample)
AU (1) AU2013201394B2 (enExample)
CA (1) CA2865810C (enExample)
DK (1) DK2822966T3 (enExample)
ES (1) ES2660157T3 (enExample)
WO (1) WO2013132063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102142261B1 (ko) 2012-03-09 2020-08-11 체에스엘 베링 아게 분비형 면역글로불린을 포함하는 조성물
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
CA3043012A1 (en) 2016-11-10 2018-05-17 Becton, Dickinson And Company Timeline system for monitoring a culture media protocol
EP4662233A1 (en) * 2023-01-13 2025-12-17 Michael R. Simon Process for preparation of secretory iga and secretory igm and use thereof for treating necrotizing enterocolitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Also Published As

Publication number Publication date
HK1204629A1 (en) 2015-11-27
DK2822966T3 (en) 2018-02-26
AU2013201394A1 (en) 2013-09-26
WO2013132063A1 (en) 2013-09-12
CA2865810C (en) 2022-09-06
CN104254543B (zh) 2018-06-05
EP2822966A1 (en) 2015-01-14
AU2013201394B2 (en) 2015-09-03
JP2015513554A (ja) 2015-05-14
ES2660157T3 (es) 2018-03-21
JP6238910B2 (ja) 2017-11-29
KR20140145587A (ko) 2014-12-23
US9546209B2 (en) 2017-01-17
CA2865810A1 (en) 2013-09-12
US20150030613A1 (en) 2015-01-29
CN104254543A (zh) 2014-12-31
EP2822966B1 (en) 2017-11-29
EP2636683A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
EP3157565B1 (en) Treatment of polybacterials infections
US10221233B2 (en) Compositions comprising secretory-like immunoglobulins
CN104968797A (zh) 金黄色葡萄球菌表面决定簇的抗体
KR102120620B1 (ko) 면역글로불린을 이용한 점막염의 치료
JP6371758B2 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
JP2025165988A (ja) プラスミノーゲンとの結合のための抗体
WO2004083425A1 (ja) 歯周病治療剤
HK1204629B (en) Treatment of mucositis with immunoglobulin a
US20210017257A1 (en) Compositions and Methods for Treating and Preventing Staphylococcus Aureus Infections
HK1236126A1 (en) Treatment of polybacterials infections
HK1236126B (en) Treatment of polybacterials infections
HK1229710A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190318

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191210

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190318

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191210

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190819

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180228

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200402

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200310

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191210

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190819

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180228

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200603

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200604

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230418

Start annual number: 4

End annual number: 4